No association of CpG island methylator phenotype and colorectal cancer survival: population-based study
- PMID: 27811854
- PMCID: PMC5129826
- DOI: 10.1038/bjc.2016.361
No association of CpG island methylator phenotype and colorectal cancer survival: population-based study
Abstract
Background: Previous studies have shown adverse effects of CpG island methylator phenotype (CIMP) on colorectal cancer (CRC) prognosis. However, sample sizes were often limited and only few studies were able to adjust for relevant molecular features associated with CIMP. The aim of this study was to investigate the impact of CIMP on CRC survival in a large population-based study with comprehensive adjustment.
Methods: The CIMP status and other molecular tumour features were analysed in 1385 CRC patients diagnosed between 2003 and 2010. Detailed information were obtained from standardised personal interviews and medical records. During follow-up (median: 4.9 years), we assessed vital status, cause of death and therapy details. Cox proportional hazard regression models were used to estimate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of survival after CRC.
Results: The CIMP-H occurred more frequently in patients with older age, female gender, cancer in the proximal colon, BRAF mutation and microsatellite instability-high (MSI-H). However, CIMP status was not associated with CRC prognosis in CRC patients (HR=1.00; 95% CI=0.72-1.40 for overall survival; HR=0.96; 95% CI=0.65-1.41 for disease-specific survival) or in any of the subgroups. Although CIMP status was associated with the presence of MSI-H and BRAF mutation, the prognostic effects of MSI-H (HR=0.49; 95% CI=0.27-0.90) and BRAF mutation (HR=1.78; 95% CI=1.10-2.84) were independent of CIMP status. Similar benefit of chemotherapy was found for CRC outcomes in both the CIMP-low/negative group and the CIMP-high group.
Conclusions: CpG island methylator phenotype was not associated with CRC prognosis after adjusting for other important clinical factors and associated mutations.
Similar articles
-
Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.Pathol Int. 2008 Feb;58(2):104-13. doi: 10.1111/j.1440-1827.2007.02197.x. Pathol Int. 2008. PMID: 18199160
-
A prognostic CpG score derived from epigenome-wide profiling of tumor tissue was independently associated with colorectal cancer survival.Clin Epigenetics. 2019 Jul 24;11(1):109. doi: 10.1186/s13148-019-0703-4. Clin Epigenetics. 2019. PMID: 31340858 Free PMC article.
-
The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status.Clin Cancer Res. 2010 Mar 15;16(6):1845-55. doi: 10.1158/1078-0432.CCR-09-2594. Epub 2010 Mar 2. Clin Cancer Res. 2010. PMID: 20197478
-
Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis.Ann Oncol. 2014 Dec;25(12):2314-2327. doi: 10.1093/annonc/mdu149. Epub 2014 Apr 8. Ann Oncol. 2014. PMID: 24718889 Free PMC article. Review.
-
Methylator phenotype in colorectal cancer: A prognostic factor or not?Crit Rev Oncol Hematol. 2016 Mar;99:74-80. doi: 10.1016/j.critrevonc.2015.11.001. Epub 2015 Dec 7. Crit Rev Oncol Hematol. 2016. PMID: 26702883 Review.
Cited by
-
Validation of Genetic Markers Associated with Survival in Colorectal Cancer Patients Treated with Oxaliplatin-Based Chemotherapy.Cancer Epidemiol Biomarkers Prev. 2022 Feb;31(2):352-361. doi: 10.1158/1055-9965.EPI-21-0814. Epub 2021 Dec 3. Cancer Epidemiol Biomarkers Prev. 2022. PMID: 34862210 Free PMC article.
-
Clinical, Pathological, and Molecular Characteristics of CpG Island Methylator Phenotype in Colorectal Cancer: A Systematic Review and Meta-analysis.Transl Oncol. 2018 Oct;11(5):1188-1201. doi: 10.1016/j.tranon.2018.07.008. Epub 2018 Jul 30. Transl Oncol. 2018. PMID: 30071442 Free PMC article.
-
Multiple gene promoter methylation and clinical stage in adjacent normal tissues: Effect on prognosis of colorectal cancer in Taiwan.Sci Rep. 2020 Jan 10;10(1):145. doi: 10.1038/s41598-019-56691-6. Sci Rep. 2020. PMID: 31924802 Free PMC article.
-
Colorectal Cancers: An Update on Their Molecular Pathology.Cancers (Basel). 2018 Jan 20;10(1):26. doi: 10.3390/cancers10010026. Cancers (Basel). 2018. PMID: 29361689 Free PMC article. Review.
-
Which patients to sample in clinical cohort studies when the number of events is high and measurement of additional markers is constrained by limited resources.Cancer Med. 2020 Oct;9(20):7398-7406. doi: 10.1002/cam4.3381. Epub 2020 Aug 19. Cancer Med. 2020. PMID: 32813923 Free PMC article.
References
-
- Blaker H, Helmchen B, Bonisch A, Aulmann S, Penzel R, Otto HF, Rieker RJ (2004) Mutational activation of the RAS-RAF-MAPK and the Wnt pathway in small intestinal adenocarcinomas. Scand J Gastroenterol 39(8): 748–753. - PubMed
-
- Brenner H, Chang-Claude J, Jansen L, Knebel P, Stock C, Hoffmeister M (2014) Reduced risk of colorectal cancer up to 10 years after screening, surveillance, or diagnostic colonoscopy. Gastroenterology 146(3): 709–717. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials